| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 25.05.
| High Profitability and Low Valuation for Gilead | | 4 | Motley Fool |
| 24.05.
| Gilead Drug Up for European Review | | 1 | Zacks |
| 24.05.
| Gilead reicht Europäischen Marktantrag für Arzneimittelverstärker Cobicistat ein | | 58 | Business Wire |
| Gilead Sciences, Inc. (NASDAQ: GILD) hat heute bekannt gegeben, dass der
Marktzulassungsantrag (MAA) für Cobicistat, der am 26. April 2012
gestellt wurde, von der Europäischen...
Mehr lesen zu:
Gilead reicht Europäischen Marktantrag für Arzneimittelverstärker Cobicistat ein | |
| 24.05.
| Erfolg für GILEAD | | 86 | Bernecker Börsenbriefe |
| Gilead kann sich gleich zweimal freuen: Ein Expertengremium hat kurz nacheinander die Zulassung zweier neuer Gilead-Medikamente empfohlen - beide ranken sich um die Krankheut HIV, teilweise mit einem...
Mehr lesen zu:
Erfolg für GILEAD | |
| 23.05.
| Gilead Sciences Says MAA For Cobicistat Validated By European Medicines Agency | | 61 | AFX News |
| FOSTER CITY (dpa-AFX) - Gilead Sciences Inc. (GILD) announced that the
Marketing Authorisation Application or MAA for cobicistat, submitted on April
26, 2012, has been validated by the European...
Mehr lesen zu:
Gilead Sciences Says MAA For Cobicistat Validated By European Medicines Agency | |
| 23.05.
| Gilead Files European Marketing Application for Boosting Agent Cobicistat | | 52 | Business Wire |
| Gilead Sciences, Inc. (Nasdaq: GILD) announced today that the Marketing
Authorisation Application (MAA) for cobicistat, submitted on April 26,
2012, has been validated...
Mehr lesen zu:
Gilead Files European Marketing Application for Boosting Agent Cobicistat | |
| 21.05.
| Gilead Sciences Inc.: Strong Growth At A Low Price | | 17 | Seeking Alpha |
| 21.05.
| Shares of Gilead Sciences Rank the Lowest in Terms of EPS Growth in the Biotechnology Industry | | 4 | SmarTrend |
| 15.05.
| Possible Bearish Inside Day Candle Pattern Detected for Gilead Sciences | | 12 | SmarTrend |
| 15.05.
| The Zacks Analyst Blog Highlights: Gilead Sciences, Abbott Labs, Alliance Data Systems Corporation, Blue Nile and Bristol-Myers Squibb | | 46 | PR Newswire |
| CHICAGO, May 15, 2012 /PRNewswire/ --Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting...
Mehr lesen zu:
The Zacks Analyst Blog Highlights: Gilead Sciences, Abbott Labs, Alliance Data Systems Corporation, Blue Nile and Bristol-Myers Squibb | |
| 14.05.
| Good News for Gilead | | 33 | Zacks |
| 14.05.
| HIV Drug Maker Gilead Sciences Scores Two Wins | | 8 | Benzinga.com |
| 14.05.
| HIV Drug Maker Gilead Sciences Scores Two Wins | | 7 | Minyanville |
| 14.05.
| FDA advisory committee recommends Gilead HIV drug | | 15 | Pharma Bus Review |
| 11.05.
| Gilead Sciences HIV Drug Quad Gets FDA Panel Backing | | 118 | AFX News |
| FOSTER CITY (dpa-AFX) - Gilead Sciences Inc. (GILD) Friday said that its
experimental drug for treating HIV, known as Quad, won the backing of an FDA
advisory panel.The Antiviral Drugs Advisory...
Mehr lesen zu:
Gilead Sciences HIV Drug Quad Gets FDA Panel Backing | |
| 11.05.
| FDA Advisory Panel Oks Gilead's Once-Daily Quad Single Tablet Regimen For HIV | | 113 | AFX News |
| FOSTER CITY (dpa-AFX) - Gilead Sciences Inc. (GILD) announced that the
Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration or
FDA has voted 13 to 1 in support of...
Mehr lesen zu:
FDA Advisory Panel Oks Gilead's Once-Daily Quad Single Tablet Regimen For HIV | |
| 11.05.
| Gilead Sciences (GILD) Gets FDA Advisory Committee Support of Quad HIV-1 Treatment | | 4 | StreetInsider.com |
| 11.05.
| UPDATE: FDA Advisory Committee Supports Approval of Gilead's Once-Daily Quad Single Tablet Regimen for HIV | | 2 | Benzinga.com |
| 11.05.
| FDA Advisory Committee Supports Approval of Gilead's Once-Daily Quad Single Tablet Regimen for HIV | | 77 | Business Wire |
| – Final FDA Decision On The Quad Anticipated Late Summer –
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Antiviral
Drugs Advisory Committee...
Mehr lesen zu:
FDA Advisory Committee Supports Approval of Gilead's Once-Daily Quad Single Tablet Regimen for HIV | |
| 11.05.
| Gilead Sciences Clears Hurdle for First Pill to Prevent HIV | | 3 | Minyanville |
